Earnings release · WST
West Reports Third-Quarter 2026 Results
West Pharmaceutical Services Inc. · Filed · SEC Form 8-K, Item 2.02
West Pharmaceutical Services Inc. company page Original on SEC.gov ↗
Revenue
$728.8 million
+12.6% vs a year ago
EPS
$3.02
+57.3% vs a year ago
Guidance
raisedoutlook statement
Automated extract. The items below were picked out of the company's press release by software and may be wrong or incomplete.
Please read the original before relying on any figure. Not investment advice.
Why it matters
Revenue climbed 12.6% year on year to $728.8 million, and EPS rose 57.3% to $3.02. Sales and earnings both ahead of a year ago is generally the cleaner kind of result. The company lifted its guidance, which is usually read as management's view of coming periods improving.
Written automatically by Stocknote's note engine from the figures on this page and the company's previous release. Every number in this note is checked against those figures. Not investment advice.
What the company states
Revenue
$728.8 million +12.6% vs a year ago
…Net sales of $728.8 million grew by 12.6% and increased 16.6% on an organic basis.…
EPS
$3.02 +57.3% vs a year ago
…Diluted earnings per share ("EPS") of $3.02 increased 57.3%.…
Guidance
Guidance raised
…Raising Full-Year Net Sales and Adjusted-Diluted EPS guidance.…
Trend: last 1 reports
All releases →Revenue growth (YoY)
EPS growth (YoY)
Disclaimer: This page is generated automatically from public SEC filings for information only. Stocknote does not edit the company's release and does not guarantee the accuracy of the extracted items. Read the full disclaimer here.